Business Standard

SPARC raises over Rs 1,110 cr; issues warrants to Dilip Shanghvi, others

Sun Pharma Advanced Research Company on Thursday said it has raised over Rs 1,112 crore by way of issuing warrants to the company's promoter Dilip Shanghvi and other entities

Drug discovery co SPARC seeks Sebi nod for Rs 250-cr rights issue (spot)

Press Trust of India New Delhi

Sun Pharma Advanced Research Company (SPARC) on Thursday said it has raised over Rs 1,112 crore by way of issuing warrants to the company's promoter Dilip Shanghvi and other entities.

"The securities allotment committee of the board of directors of the company, has considered and approved the allotment of 6,24,74,082 warrants on preferential basis at an issue price of Rs 178 each aggregating to Rs 1,112.03 crore to Dilip Shantilal Shanghvi, promoter of the company and to certain other non-promoter persons/ entities," SPARC said in a regulatory filing.

The issue price includes the warrant subscription price (Rs. 44.50 per warrant) and the warrant exercise price (Rs. 133.50 per warrant).

 

The company had initially planned to raise Rs 1,200 crore.

"As against the approval for issue of 6,74,70,203 warrants, the committee has allotted only 6,24,74,082 warrants, due to, non-receipt of warrant subscription money by the proposed allottees and / or non- receipt of in-principle approval from the stock exchanges on some warrants," the company added.

The company said it has issued 3,37,07,865 out of the total 6,24,74,082 warrants to Shanghvi. Shares of SPARC were trading 2.42 per cent higher at Rs 252.30 apiece on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 08 2021 | 1:31 PM IST

Explore News